title: Endometrioid carcinoma of the ovary. Retrospective study.
abstract: From 1985 to 1991, 9 patients with endometrioid carcinoma of the ovary were treated and followed at the University of Ancona, Department of Gynecology and Obstetrics. Four patients (44.4%) had Stage I disease, 1 (11.1%) Stage II, 1 (11.1%) Stage III and 3 (33.3%) Stage IV. Six patients (66.6%) had grade 2 of the disease and 3 (33.3%) grade 3. Two of the patients (22.2%) had synchronous endometrial carcinoma while 3 had histologic evidence of endometriosis at the time of presentation. All the patients received treatment of combination of surgery, polychemotherapy, hormone and/or immunotherapy. The overall survival rate after a median follow up of 26.6 months was 66.6%. A high survival (100%) was observed for patients with associated endometriosis.
authors: Department of Gynecology and Obstetrics University of Ancona, Italy.
authors: G G
authors: GG
authors: Garzetti
authors: A
authors: A
authors: Ciavattini
authors: G
authors: G
authors: Goteri
authors: M
authors: M
authors: De Nictolis
authors: M
authors: M
authors: Cignitti
authors: A L
authors: AL
authors: Tranquilli
authors: C
authors: C
authors: Romanini
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004715:Endometriosis / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D013629:Tamoxifen; D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D008525:Medroxyprogesterone; D002945:Cisplatin